Search

Becton Dickinson and Co

Atvērts

SektorsVeselības aprūpe

183.61 1.86

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

179.97

Max

182.1

Galvenie mērījumi

By Trading Economics

Ienākumi

759M

449M

Pārdošana

269M

5B

P/E

Sektora vidējais

31.645

56.432

EPS

3.23

Dividenžu ienesīgums

2.36

Peļņas marža

9.011

Darbinieki

72,000

EBITDA

-23M

686M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+6.97% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.36%

2.27%

Nākamie ieņēmumi

2026. g. 5. nov.

Nākamais dividenžu datums

2026. g. 30. sept.

Nākamais Ex dividenžu datums

2026. g. 7. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.2B

50B

Iepriekšējā atvēršanas cena

181.75

Iepriekšējā slēgšanas cena

183.61

Ziņu noskaņojums

By Acuity

52%

48%

247 / 339 Rangs Healthcare

Becton Dickinson and Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 19:52 UTC

Becton Dickinson and Co is trading modestly higher amid a broader market divergence from the recent trend of higher daily closes since Thursday.

2026. g. 17. sept. 20:07 UTC

Becton Dickinson and Co shares fell modestly on Thursday, closing below the 20-day moving average and near the lower end of their one-month range.

2026. g. 16. sept. 19:04 UTC

Becton Dickinson and Co shares fell sharply, reversing a trend of higher daily closes observed since Tuesday's close.

2026. g. 15. sept. 20:13 UTC

Becton Dickinson and Co shares are lower in after-market hours amid broader market caution following a decline in the manufacturing index and inflation concerns.

2026. g. 14. sept. 22:31 UTC

Becton Dickinson and Co is trading higher in after-market hours, continuing a trend from the past three sessions amid broader market dynamics and inflation concerns.

2026. g. 11. sept. 20:31 UTC

Becton Dickinson and Co shares are lower in after-market hours amid broader market weakness and speculation over potential Federal Reserve interest rate hikes.

2026. g. 10. sept. 20:01 UTC

Becton Dickinson shares are lower today, reflecting ongoing weakness amid a broader market backdrop following the European Central Bank's interest rate hike.

2026. g. 9. sept. 20:07 UTC

Becton Dickinson and Co's shares are higher today amid routine trading. No specific news has been identified to explain the movement.

2026. g. 8. sept. 23:41 UTC

Becton Dickinson and Co shares rose in after-market trading, recovering from earlier losses. The price remains below its 20-day moving average.

2026. g. 4. sept. 20:08 UTC

Becton Dickinson is lower today amid broader market declines following a strong jobs report that has pressured risk assets. No specific company news was identified.

2026. g. 2. sept. 20:08 UTC

Becton Dickinson shares are higher today, continuing a trend of slight gains since Tuesday's close, despite a minor pullback during the session.

2026. g. 1. sept. 23:56 UTC

Becton Dickinson and Co shares rose in after-market trading, reflecting a position above its 20-day moving average and near the top of its one-month range.

2026. g. 31. aug. 21:03 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining a strong upward trajectory above the 20-day moving average. No specific news was identified.

2026. g. 28. aug. 20:08 UTC

Becton Dickinson shares are higher, reflecting gains since Thursday. The stock earlier reached a session high before pulling back slightly.

2026. g. 27. aug. 22:26 UTC

Becton Dickinson and Co shares are trading higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026. g. 26. aug. 20:08 UTC

Becton Dickinson shares are higher today amid mixed market performance and recent inflation data, with no specific news identified to explain the movement.

2026. g. 25. aug. 23:36 UTC

Becton Dickinson shares are higher in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

2026. g. 24. aug. 19:46 UTC

Becton Dickinson is trading lower, influenced by rising oil prices and geopolitical tensions. The stock reached a session high earlier but has since declined.

2026. g. 21. aug. 23:01 UTC

Becton Dickinson shares are lower in after-market trading, following unusual activity despite a strong one-month gain and trading above the 20-day moving average.

2026. g. 20. aug. 20:06 UTC

Becton Dickinson and Co is trading higher, maintaining an upward trajectory since Wednesday's close, despite some intraday volatility. No specific news was identified.

2026. g. 19. aug. 21:01 UTC

Becton Dickinson and Co shares are lower in after-market trading, showing unusual weakness despite remaining above the 20-day moving average. No specific news was identified.

2026. g. 18. aug. 19:46 UTC

Becton Dickinson and Co shares are lower today, breaking a trend of higher daily closes amid rising Treasury yields and inflation concerns.

2026. g. 17. aug. 23:01 UTC

News

Becton Dickinson appoints Gary Sorsher as executive vice president and chief quality officer, effective September 8. Shares are higher in after-market trading.

2026. g. 14. aug. 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

2026. g. 13. aug. 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

2026. g. 12. aug. 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

2026. g. 11. aug. 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

2026. g. 10. aug. 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

2026. g. 7. aug. 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

2026. g. 6. aug. 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Becton Dickinson and Co Prognoze

Cenas mērķis

By TipRanks

6.97% augšup

Prognoze 12 mēnešiem

Vidējais 193.3 USD  6.97%

Augstākais 210 USD

Zemākais 175 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Becton Dickinson and Co — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

5

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

247 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.